<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046510</url>
  </required_header>
  <id_info>
    <org_study_id>Ocytocin in c section</org_study_id>
    <nct_id>NCT04046510</nct_id>
  </id_info>
  <brief_title>Comparaison of 3 Protocols of Ocytocin Administration in C Section</brief_title>
  <official_title>Comparaison of 3 Protocols of Ocytocin Administration in Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mongi Slim Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mongi Slim Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to compare 3 doses of ocytocin in bolus injection and contnious perfusion
      during C section. these doses determined by: high, intermediate and low doses, were
      administred to parturients during elective or urgent C section under spinal anesthesia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aimed to compare 3 doses of ocytocin in bolus injection and contnious perfusion
      during C section. these doses determined by: high, intermediate and low doses, were
      administred to parturients during elective or urgent C section under spinal anesthesia.

      The aim was to determine the lowest efficient dose to prevent post partum hemorrage and with
      the lowest incidence of maternal side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>pre filled syringues of ocytocin were given to the care provider who didn't know the exact amount of ocytocin bolus and continious infusion</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>uterine tone</measure>
    <time_frame>10 minutes</time_frame>
    <description>uterine tone juged by the obstetrician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemoglobin rate</measure>
    <time_frame>30 minutes after C section</time_frame>
    <description>delta hemoglobin: preoperative HB- Post operative HB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additive boluses of Ocytocin</measure>
    <time_frame>30 minutes after C section</time_frame>
    <description>necessity of Additive boluses of Ocytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects of Ocytocin</measure>
    <time_frame>up to 30 minutes after C section</time_frame>
    <description>Tachycardia, hypotension, nausea vomiting, headache, chest pain</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Cesarean Section Complications</condition>
  <condition>Oxytocin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>High doses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patients of this group recieved conventionnal doses of ocytocin after foetal extraction in C section: 5IU in bolus followed by 15IU in continuous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 10IU in continuous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 5 IU in continuous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocytocin</intervention_name>
    <description>Administration of lower doses of Ocytocin in bolus and continuous infusion</description>
    <arm_group_label>High doses</arm_group_label>
    <arm_group_label>Intermediate doses</arm_group_label>
    <arm_group_label>Low doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients scheduled for C section under spinal anesthesia, monofoetal
             pregnancy, full term

        Exclusion Criteria:

          -  necessity of general anesthesia

          -  non conscent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>including only parturients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mongi Slim Hospital</name>
      <address>
        <city>Tunis</city>
        <zip>2046</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mongi Slim Hospital</investigator_affiliation>
    <investigator_full_name>Mhamed Sami Mebazaa</investigator_full_name>
    <investigator_title>Professor head of the anesthesia and intensive care department</investigator_title>
  </responsible_party>
  <keyword>Cesarean section, ocytocin, uterine tone, side effects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

